How Lokelma Works to Lower Blood Potassium
Lokelma (sodium zirconium cyclosilicate) is a selective potassium binder taken orally to treat hyperkalemia, high blood potassium levels. It exchanges sodium ions for potassium ions in the gastrointestinal tract, trapping potassium and preventing its absorption into the bloodstream.[1]
Particles of Lokelma have a rigid crystalline structure with cavities sized to fit dehydrated potassium ions (K+). In the stomach and intestines, these particles release sodium ions (Na+) in exchange for potassium ions from food or gut secretions. The bound potassium forms insoluble complexes that pass through the intestines and exit in stool, reducing overall potassium uptake into the blood.[1][2]
This process starts quickly—potassium levels often drop within 1 hour of the first dose, with peak effects around 2-4 hours, due to the drug's high selectivity (over 98% for potassium vs. other ions like calcium or magnesium).[2]
How It Differs from Other Potassium Binders
Unlike older binders like sodium polystyrene sulfonate (Kayexalate), which work more slowly (hours to days) and non-selectively in the colon, Lokelma acts in the upper gut with minimal systemic absorption. It avoids risks like bowel necrosis associated with polystyrene sulfonate.[1][3]
| Binder | Site of Action | Onset | Key Difference |
|--------|---------------|--------|---------------|
| Lokelma | Stomach/intestines | 1 hour | Highly selective, no sodium load issues |
| Patiromer (Veltassa) | Colon | 7 hours | Polymer-based, binds over wider pH range |
| Sodium polystyrene sulfonate | Colon | 24+ hours | Non-specific, higher GI risks |
When Does It Start Working and How Long Does It Last
A single 10g dose binds up to 5-7 mEq of potassium. For acute hyperkalemia, loading doses (3x10g daily for 48 hours) normalize levels in most patients within 48 hours. Maintenance is 10g once daily, sustaining control during ongoing risks like kidney disease or heart failure meds (e.g., ACE inhibitors).[2][4]
Common Side Effects and Patient Concerns
Mild GI issues like constipation or nausea occur in <10% of users. It raises stool sodium slightly but doesn't worsen hypertension or edema in trials. Rare edema reports led to monitoring in heart failure patients. No long-term data beyond 1-2 years.[1][4]
Who Makes Lokelma and Availability
AstraZeneca manufactures and markets Lokelma, FDA-approved in 2018 for adults with hyperkalemia.[1] It's available as oral powder packets (5g, 10g doses), priced around $25-30 per 10g dose without insurance (U.S. averages).[5]
Sources
[1]: Lokelma Prescribing Information (AstraZeneca)
[2]: NEJM Study on Sodium Zirconium Cyclosilicate
[3]: FDA Approval Summary
[4]: Clinical Pharmacology Review